Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

Phase II study of chemoembolization with drug-eluting beads in patients with hepatic neuroendocrine metastases: high incidence of biliary injury.

Bhagat N, Reyes DK, Lin M, Kamel I, Pawlik TM, Frangakis C, Geschwind JF.

Cardiovasc Intervent Radiol. 2013 Apr;36(2):449-59. doi: 10.1007/s00270-012-0424-y. Epub 2012 Jun 22.

2.

Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States.

Reyes DK, Vossen JA, Kamel IR, Azad NS, Wahlin TA, Torbenson MS, Choti MA, Geschwind JF.

Cancer J. 2009 Nov-Dec;15(6):526-32. doi: 10.1097/PPO.0b013e3181c5214b.

3.

Transarterial chemoembolization of liver metastases from well differentiated gastroenteropancreatic endocrine tumors with doxorubicin-eluting beads: preliminary results.

de Baere T, Deschamps F, Teriitheau C, Rao P, Conengrapht K, Schlumberger M, Leboulleux S, Baudin E, Hechellhammer L.

J Vasc Interv Radiol. 2008 Jun;19(6):855-61. doi: 10.1016/j.jvir.2008.01.030. Epub 2008 Mar 19.

PMID:
18503899
4.

Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma.

Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, Geschwind JF.

J Clin Oncol. 2011 Oct 20;29(30):3960-7. doi: 10.1200/JCO.2011.37.1021. Epub 2011 Sep 12. Erratum in: J Clin Oncol. 2011 Dec 1;29(34):4596-8.

5.

Transarterial hepatic chemoembolization with 70-150 ┬Ám drug-eluting beads: assessment of clinical safety and liver toxicity profile.

Odisio BC, Ashton A, Yan Y, Wei W, Kaseb A, Wallace MJ, Vauthey JN, Gupta S, Tam AL.

J Vasc Interv Radiol. 2015 Jul;26(7):965-71. doi: 10.1016/j.jvir.2015.03.020. Epub 2015 Jun 5.

6.

Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC.

Prajapati HJ, Xing M, Spivey JR, Hanish SI, El-Rayes BF, Kauh JS, Chen Z, Kim HS.

AJR Am J Roentgenol. 2014 Dec;203(6):W706-14. doi: 10.2214/AJR.13.12308.

PMID:
25415737
7.

Conventional versus Drug-Eluting Bead Transarterial Chemoembolization for Neuroendocrine Tumor Liver Metastases.

Makary MS, Kapke J, Yildiz V, Pan X, Dowell JD.

J Vasc Interv Radiol. 2016 Sep;27(9):1298-1304. doi: 10.1016/j.jvir.2016.05.014. Epub 2016 Aug 4.

PMID:
27499157
8.

Liver and biliary damages following transarterial chemoembolization of hepatocellular carcinoma: comparison between drug-eluting beads and lipiodol emulsion.

Monier A, Guiu B, Duran R, Aho S, Bize P, Deltenre P, Dunet V, Denys A.

Eur Radiol. 2017 Apr;27(4):1431-1439. doi: 10.1007/s00330-016-4488-y. Epub 2016 Jul 19.

PMID:
27436016
9.

Doxorubicin-loaded drug-eluting beads versus conventional transarterial chemoembolization for nonresectable hepatocellular carcinoma.

Arabi M, BenMousa A, Bzeizi K, Garad F, Ahmed I, Al-Otaibi M.

Saudi J Gastroenterol. 2015 May-Jun;21(3):175-80. doi: 10.4103/1319-3767.157571. Erratum in: Saudi J Gastroenterol. 2015 Jul-Aug;21(4):264.

10.

Safety and efficacy of drug-eluting bead chemoembolization for hepatocellular carcinoma: comparison of small-versus medium-size particles.

Padia SA, Shivaram G, Bastawrous S, Bhargava P, Vo NJ, Vaidya S, Valji K, Harris WP, Hippe DS, Kogut MJ.

J Vasc Interv Radiol. 2013 Mar;24(3):301-6. doi: 10.1016/j.jvir.2012.11.023. Epub 2013 Feb 4.

PMID:
23380737
11.

A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead.

Poon RT, Tso WK, Pang RW, Ng KK, Woo R, Tai KS, Fan ST.

Clin Gastroenterol Hepatol. 2007 Sep;5(9):1100-8. Epub 2007 Jul 12.

PMID:
17627902
12.

Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma.

Prajapati HJ, Dhanasekaran R, El-Rayes BF, Kauh JS, Maithel SK, Chen Z, Kim HS.

J Vasc Interv Radiol. 2013 Mar;24(3):307-15. doi: 10.1016/j.jvir.2012.11.026. Epub 2013 Jan 29.

PMID:
23375519
13.

Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.

Green TJ, Rochon PJ, Chang S, Ray CE Jr, Winston H, Ruef R, Kreidler SM, Glueck DH, Shulman BC, Brown AC, Durham J.

J Vasc Interv Radiol. 2013 Nov;24(11):1613-22. doi: 10.1016/j.jvir.2013.07.024. Epub 2013 Sep 20.

PMID:
24060436
14.

Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy.

Kuhlmann JB, Euringer W, Spangenberg HC, Breidert M, Blum HE, Harder J, Fischer R.

Eur J Gastroenterol Hepatol. 2012 Apr;24(4):437-43. doi: 10.1097/MEG.0b013e3283502241.

PMID:
22261548
15.
16.

Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial.

Vogl TJ, Lammer J, Lencioni R, Malagari K, Watkinson A, Pilleul F, Denys A, Lee C.

AJR Am J Roentgenol. 2011 Oct;197(4):W562-70. doi: 10.2214/AJR.10.4379.

PMID:
21940527
17.

Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm follow-up.

Dekervel J, van Malenstein H, Vandecaveye V, Nevens F, van Pelt J, Heye S, Laleman W, Van Steenbergen W, Vaninbroukx J, Verslype C, Maleux G.

J Vasc Interv Radiol. 2014 Feb;25(2):248-55.e1. doi: 10.1016/j.jvir.2013.10.017. Epub 2013 Dec 2.

PMID:
24295569
18.

Intraprocedural C-arm dual-phase cone-beam CT: can it be used to predict short-term response to TACE with drug-eluting beads in patients with hepatocellular carcinoma?

Loffroy R, Lin M, Yenokyan G, Rao PP, Bhagat N, Noordhoek N, Radaelli A, Blijd J, Liapi E, Geschwind JF.

Radiology. 2013 Feb;266(2):636-48. doi: 10.1148/radiol.12112316. Epub 2012 Nov 9.

19.

Doxorubicin-eluting bead vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma before liver transplantation.

Nicolini D, Svegliati-Baroni G, Candelari R, Mincarelli C, Mandolesi A, Bearzi I, Mocchegiani F, Vecchi A, Montalti R, Benedetti A, Risaliti A, Vivarelli M.

World J Gastroenterol. 2013 Sep 14;19(34):5622-32. doi: 10.3748/wjg.v19.i34.5622.

20.

Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: lipiodol vs. drug-eluting beads.

Guiu B, Deschamps F, Aho S, Munck F, Dromain C, Boige V, Malka D, Leboulleux S, Ducreux M, Schlumberger M, Baudin E, de Baere T.

J Hepatol. 2012 Mar;56(3):609-17. doi: 10.1016/j.jhep.2011.09.012. Epub 2011 Oct 23.

PMID:
22027582

Supplemental Content

Support Center